EN DE
Watch ViGenCell Inc. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

ViGenCell Inc. (308080) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of ViGenCell Inc. stock KRW 1,154, price KRW 4,370, that is 73.6% below the price, quality 32 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR

VI ViGenCell Inc. logo Thin data Nov 4, 2026

ViGenCell Inc.

308080 · KQ
Very expensive, weak quality

Our calculation puts a fair price 74% below what the stock costs today.

Low debt
Fair value 1,154 KRW · Strongly overvalued
Quality 32/100
Weak Growth (revenue YoY −91.9 %/yr in KRW)
Negative free cash flow
Trails peers (1/7)
Narrow moat 5/100
Thin data
Watch ViGenCell Inc. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

30,500 KRW 2,345 KRW Fair Value 1,154 KRW Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.

How to read this chart

60‑month range 2,345 KRW – 30,500 KRW · fair‑value band 761.31 KRW – 1,442 KRW · the 4,370 KRW price screens above the 1,154 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.

Follow ViGenCell in your weekly email

Every Wednesday you see whether ViGenCell is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

ViGenCell Inc. provides immune cell therapy in South Korea.

Show moreShow less

It develops ViTier, an antigen-specific killer T cell therapy, such as VT-EBV-N for NK/T Lymphoma indications and VT-Tri(1)-A for AML indications; ViMedier, a cord blood-derived myeloid suppressor cell therapy, including VM-GD for GvHD indications and VM-AD for atopic dermatitis indications; and ViRanger, an off-the-shelf allogenic universal T cell gene therapy comprising VR-CAR and VR-GDT for hepatoma and leukemia indications.

The company was founded in 2013 and is based in Seoul, South Korea.

Stock analysis

ViGenCell Inc. (308080) currently trades at 4,370 KRW, while our model-based Fair Value estimate is 1,154 KRW, 74% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the data coverage at low.

Scenario range: 761.31 KRW (bear) to 1,442 KRW (bull), the price of 4,370 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 32/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak, negative or inconsistent.

ViGenCell Inc. reported revenue of 22.7M KRW in FY2025 versus 0 KRW in FY2020. Reported net income was −16.3B KRW in FY2025.

Key figures

Market cap 93.7B KRW (≈ $69.3M) Micro · EPS (TTM) −612.64 KRW · Return on equity −20.2% · Return on assets (EBIT) −21.7% (5-year average) · Operating margin −4,862% · Free cash flow −14.6B KRW · Net debt 3.5B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 5 out of 100 (medium confidence).

What moves the price

The share trades about 72% below its 52-week high and 41% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −74%, 308080 screens richer than that median.

Fair Value models

Bear 761.31 KRW Fair Value 1,154 KRW Bull 1,442 KRW
Price 4,370 KRW · Downside -73.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) 761.31 KRW 1,154 KRW 1,442 KRW 54
All 1 models by family
Asset-Based
NCAV (Graham) 761.31 KRW 1,154 KRW 1,442 KRW 54

Open the full fair value analysis →

Quality Score breakdown

Overall quality 32/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 30
Are margins and returns getting better?
Cashflow 8
Do the profits arrive as real cash?
Financial strength 68
Debt, balance sheet and risk of trouble
Investment 67
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 41
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 36
Distance to the 52-week high, does not count
New shares 38
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is weak, negative or inconsistent.
Revenue growth 1 year
−91.9%
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.1%
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

308080 screens overvalued: fair value 74% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare ViGenCell Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks

Beats the industry median on 1/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 32 · Bottom 25%
Fair Value upside −73.6% · Bottom 25%
Profitability
Return on assets −30.1% · Below median
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Above median
Balance sheet
Debt / equity 0.17× · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 2.14× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)92 · sector 97
DIVIDEND (yield)0 · sector 22

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs 308080
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs 308080
Vertex Pharmaceuticals Incorporated VRTX $547.09 $601.80 +10% vs 308080
Samsung Biologics Co 207940 1,516,000 KRW 1,667,600 KRW +10% vs 308080
Genmab A/S GMAB kr 3,527 kr 3,880 +10% vs 308080
WuXi Biologics (Cayman) Inc 2269 HK$47.62 HK$52.38 +10% vs 308080
argenx SE ARGX $927.21 $908.40 −2% vs 308080
CSL Limited CSL A$200.77 A$183.04 −9% vs 308080
Celltrion, Inc 068270 211,000 KRW 74,945 KRW −64% vs 308080
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs 308080

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

ViGenCell Inc.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "ViGenCell Inc. Fair Value". https://www.fairvalue-calculator.com/stock/308080

Frequently asked questions

Is ViGenCell Inc. (308080) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of 1,154 KRW versus a price of 4,370 KRW, about 74% lower (overvalued).
What is the fair value of 308080?
Our model-based fair value for ViGenCell Inc. is 1,154 KRW (as of Nov 4, 2026), built from audited fundamentals. The current price: 4,370 KRW.
What is the quality score of 308080?
ViGenCell Inc. has a Quality Score of 32/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for ViGenCell Inc. (308080)?
Our model-based price target is the fair value of 1,154 KRW (as of Nov 4, 2026) from 1 valuation models. Cautious scenario 761.31 KRW, optimistic scenario 1,442 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the ViGenCell Inc. stock forecast for 2026?
Our models put fair value at 1,154 KRW, about 74% lower versus a price of 4,370 KRW (overvalued). Cautious scenario 761.31 KRW, optimistic scenario 1,442 KRW. The calculation is refreshed regularly with new filings.
What is the intrinsic value of ViGenCell Inc. (308080)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For ViGenCell Inc. it is 1,154 KRW per share (as of Nov 4, 2026), against a price of 4,370 KRW. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is ViGenCell Inc. stock overvalued or undervalued in 2026?
As of Nov 4, 2026, 308080 trades above its calculated fair value: price 4,370 KRW, fair value 1,154 KRW, a gap of about −74% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 308080?
No. The price is what the market pays today (4,370 KRW); the fair value is what the company's own numbers justify (1,154 KRW). For ViGenCell Inc. the two are 3,217 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is ViGenCell Inc. worth?
The market values ViGenCell Inc. at about 93.7B KRW (market capitalisation, as of Nov 4, 2026). Per share that is 4,370 KRW; our models calculate a fair value of 1,154 KRW per share.
What do the bullish and bearish scenarios say about 308080?
Our models span a range for ViGenCell Inc.: cautious scenario 761.31 KRW, base 1,154 KRW, optimistic 1,442 KRW per share (as of Nov 4, 2026, price 4,370 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of ViGenCell Inc. (308080)?
Balance-sheet figures for ViGenCell Inc. (as of Nov 4, 2026): return on equity −20.2%, debt of 0.17 per unit of equity. They feed the Quality Score of 32/100, which measures business quality independently of the share price.
How far is 308080 from its 52-week high?
ViGenCell Inc. trades at 4,370 KRW, about 72% below its 52-week high of 15,800 KRW and 41% above the low of 3,090 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 1,154 KRW is for.
Which stocks are comparable to ViGenCell Inc.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is ViGenCell Inc. stock attractive at the current price?
The data as of Nov 4, 2026: price 4,370 KRW, calculated fair value 1,154 KRW (−74%), Quality Score 32/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 308080 calculated?
We run ViGenCell Inc. through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of 1,154 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. ViGenCell Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of ViGenCell Inc. (308080)?
The closing price on Nov 6, 2026 was 4,370 KRW. Our model-based fair value is 1,154 KRW, about 74% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with ViGenCell Inc. right now?
The price sits above even our optimistic bull case (1,442 KRW). The favourable scenario is already priced in. Weak quality (32/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (761.31 KRW to 1,442 KRW) leaves room in how you read the outcome.

Key figures of ViGenCell Inc.

How large is the market capitalisation of ViGenCell Inc. (308080)?
The market capitalisation of ViGenCell Inc. is 93.7B KRW (≈ $69.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of ViGenCell Inc. (308080)?
Earnings per share at ViGenCell Inc. are −612.64 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of ViGenCell Inc. (308080)?
The return on equity (ROE) of ViGenCell Inc. is −20.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of ViGenCell Inc. (308080)?
On an EBIT basis the return on assets of ViGenCell Inc. is −21.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of ViGenCell Inc. (308080)?
The operating margin of ViGenCell Inc. is −4,862% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does ViGenCell Inc. (308080) generate?
The free cash flow of ViGenCell Inc. is −14.6B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does ViGenCell Inc. (308080) carry?
The net debt of ViGenCell Inc. is 3.5B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch ViGenCell Inc. in the live analysis

One click puts ViGenCell Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.